Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.53 |
| ▸ | TP53 | P04637 | 11/20 | 0.53 |
| ▸ | LMNA | P02545 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076409 | 0.89 | TP53 (0.62) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL15076592 | 0.88 | TP53 (0.61) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL19631202 | 0.86 | MAPT (0.43) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL15076571 | 0.84 | TP53 (0.62) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL15277017 | 0.84 | MAPT (0.56) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL21623174 | 0.84 | MAPT (0.63) | MAPTTP53LMNATSHRSMN1; SMN2 | |
| SCHEMBL21623578 | 0.84 | MAPT (0.63) | MAPTTP53LMNATSHRSMN1; SMN2 | |
| SCHEMBL21626418 | 0.84 | MAPT (0.63) | MAPTTP53LMNATSHRSMN1; SMN2 | |
| SCHEMBL15076380 | 0.84 | MAPT (0.63) | MAPTTP53LMNATSHRSMN1; SMN2 | |
| SCHEMBL15076587 | 0.82 | TP53 (0.66) | MAPTTP53LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | MAPT 4607/4885TP53 1486/4885LMNA 3521/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | MAPT 4607/4885TP53 1486/4885LMNA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.